This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alain M. Bron, MD; Erik A. Lippa, MD, PhD; Hans M. Hofmann, MD; Brigitte I. Feicht, MD; Jean G. Royer, MD; Françoise L. Brunner-Ferber, PhD; Deborah L. Panebianco, MS; Hans A. Von Denffer, MD

Arch Ophthalmol. 1989;107(8):1143-1146.

Abstract
• The effects on intraocular pressure of the novel topical carbonic anhydrase inhibitor MK-927 were investigated for the first time in patients. Three drops of 2% MK-927 was administered in a two-center, double-masked, randomized, placebocontrolled, two-period crossover study in 25 patients with bilateral primary open angle glaucoma or ocular hypertension. At 4.5 hours after the dose, MK-927-treated eyes demonstrated a peak mean change of –7.7 mm Hg from a mean intraocular pressure of 27.8 mm Hg immediately before the dose; this compares with a change of –3.9 mm Hg from a mean intraocular pressure of 28.2 mm Hg when the same eyes were treated with placebo. The peak mean percent change in intraocular pressure in eyes treated with MK-927 was –26.7% at 6 hours after the dose compared with a change of –13.7% after treatment with placebo. No contralateral effect on intraocular pressure due to MK-927 was observed.

Author Affiliations
From the Department of Ophthalmology, Besançon (France) University (Drs Bron and Royer); the Departments of Clinical Research (Dr Lippa), Clinical Pharmacology (Dr Brunner-Ferber), and Biostatistics (Ms Panebianco), Merck Sharp & Dohme Research Laboratories, West Point, Pa; and the Department of Ophthalmology, Technical University of Munich (West Germany) (Drs Hofmann, Feicht, and Von Denffer).

Footnotes
Accepted for publication March 21, 1989.

Reprint requests to Department of Clinical Research, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486 (Dr Lippa).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Comparison of Dorzolamide and Acetazolamide as Suppressors of Aqueous Humor Flow in Humans
Maus et al.
Arch Ophthalmol 1997;115:45-49.
ABSTRACT  

Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
Wilkerson et al.
Arch Ophthalmol 1993;111:1343-1350.
ABSTRACT  

Randomized Clinical Trials on Medical Treatment of Glaucoma: Are They Appropriate to Guide Clinical Practice?
Rossetti et al.
Arch Ophthalmol 1993;111:96-103.
ABSTRACT  

Dose Response and Duration of Action of Dorzolamide, a Topical Carbonic Anhydrase Inhibitor
Lippa et al.
Arch Ophthalmol 1992;110:495-499.
ABSTRACT  

MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in Monkeys
Wang et al.
Arch Ophthalmol 1991;109:1297-1299.
ABSTRACT  

Topically Active Carbonic Anhydrase Inhibitors for Glaucoma
Podos and Serle
Arch Ophthalmol 1991;109:38-40.
ABSTRACT  

Multiple-Dose, Dose-Response Relationship for the Topical Carbonic Anhydrase Inhibitor MK-927
Lippa et al.
Arch Ophthalmol 1991;109:46-49.
ABSTRACT  

Multiple-Dose Efficacy Comparison of the Two Topical Carbonic Anhydrase Inhibitors Sezolamide and MK-927
Bron et al.
Arch Ophthalmol 1991;109:50-53.
ABSTRACT  

MK-927: A Topical Carbonic Anhydrase Inhibitor: Dose Response and Duration of Action
Higginbotham et al.
Arch Ophthalmol 1990;108:65-68.
ABSTRACT